 Connection
Jeffrey Montgomery to Carcinoma in Situ
This is a "connection" page, showing publications Jeffrey Montgomery has written about Carcinoma in Situ.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.461 |
|
|
|
-
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.184
-
Lee MS, Shen M, Williams A, Kendrick D, Weizer A, Montgomery J. Retroureteral Small Bowel Herniation Resulting in Bowel Obstruction Following Robotic Cystectomy With Extracorporeal Ileal Conduit. Urology. 2021 01; 147:3-6.
Score: 0.179
-
Skolarus TA, Ye Z, Montgomery JS, Weizer AZ, Hafez KS, Lee CT, Miller DC, Wood DP, Montie JE, Hollenbeck BK. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
Score: 0.098
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|